Latest News and Press Releases

TORONTO, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), a global lifestyle and consumer packaged goods company at the forefront of the cannabis, beverage...

MONTREAL, Dec. 11, 2025 (GLOBE NEWSWIRE) -- PyroGenesis Inc. (“PyroGenesis”) (TSX: PYR) (OTCQX: PYRGF) (FRA: 8PY1), the leader in ultra-high temperature processes and engineering innovation, and a...

Protective Relay Market Size, Share, and Segmentation Analysis Report, By Voltage Range, Technology, Application, End-user, and Region | Forecast 2026-2033

OAKVILLE, Ontario, Dec. 11, 2025 (GLOBE NEWSWIRE) -- A new MADD Canada roadside memorial sign will be unveiled today in St. Catharines in honour of 22-year-old Cole Robert David Hodge, who was...

Opus Genetics to Present at the J.P. Morgan 2026 Healthcare Conference

MOUNTAIN VIEW, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and...

Prolynx Secures $70 Million Series A to Advance Portfolio of Ultra-Long-Acting Obesity Candidates and Appoints Chris Boulton as Chief Executive Officer

The results show, for the first time, that targeting a-syn pathology with an active immunotherapy could potentially slow the rate of progression of PD.

IMA203CD8 is a second-generation PRAME cell therapy with enhanced pharmacology in ongoing Phase 1a dose escalationManageable tolerability across all dose levelsEncouraging early clinical anti-tumor...

Dublin, Dec. 11, 2025 (GLOBE NEWSWIRE) -- The "Business Travel Management Tools Market - Global Forecast 2025-2030" has been added to ResearchAndMarkets.com's offering. Business travel...